Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer

pharmafile | August 1, 2019 | News story | Research and Development |  Cancer, Kisqali, Novartis, breast cancer, pharma 

New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in the first- and second-line treatment of hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women.

The findings showed that the combo “achieved statistically significant improvement in overall survival”, building on previous trial results that showed its benefit in prolonging life in patients. No additional safety signals were discovered.

“We are thrilled that Kisqali combination therapy again has demonstrated improved overall survival for patients with HR+/HER2- advanced breast cancer – first in pre-menopausal and peri-menopausal women in MONALEESA-7, and now in post-menopausal women in MONALEESA-3,” said Dr Susanne Schaffert, President, Novartis Oncology. “We will continue to reimagine cancer to help patients live longer, and also improve quality of life as we work towards finding a cure for this incurable disease.”

Novartis intends to reveal the full results at an upcoming medical congress, as well as submit them to global health authorities.

Matt Fellows